Group: Team

Nils Confer

Nils is the Vice President of Medical and Patient Strategies, joining Aceragen from BridgeBio where he developed Medical Affairs for rare disease programs. His prior experience includes building Medical Affairs capabilities and teams, with significant experience in the area of improving patient diagnosis capabilities. He holds and PhD in Biomedical Research from the University of

Adam Haeberle

Adam is a biopharma executive with extensive expertise in clinical, regulatory, non-clinical, CMC and commercial sciences. He will lead Aceragen’s Early Development activities, such as the identification and development of novel indications for our current pipeline programs. He will also direct evaluation and support of new opportunities that fit within Aceragen’s mission to address rare

Hien-Anh Nguyen

Hien-Anh focuses on technical operations for novel therapeutics discovery and development. She has a track-record of building multiple teams and facilities to support drug discovery, pre-clinical studies and GMP drug manufacturing. Prior to joining Aceragen, she managed the core R&D services at Exicure, assembled the tissue culture division at SAMDI Tech Inc, and led technical

Annie Cruz

Annie serves as a Regulatory Affair Associate Director. She is responsible for supporting regulatory strategy implementation from pre-IND to post-approval. In her 10 years of biopharma experience, Annie worked on multiple key functions relating to manufacture of biologics including process characterization, validation, technology transfers, GMP investigations and critical raw material assessments. She holds a doctorate

Kara Seifert

Kara serves as Executive Administrator and Accounting Associate in the finance department. Aceragen is her first foray into the world of biotechnology. She’s been an entrepreneur, a NASA research fellow, a graphic artist and a mathematical copy editor. With degrees in aeronautics & astronautics and materials science & engineering from the Massachusetts Institute of Technology,

Cody Kirk

Cody comes to Aceragen as lead financial planner having managed the PricewaterhouseCoopers (PwC) private practice for the Southeast market and assisted clients with various technical accounting matters. His portfolio includes industries such as biotech, health care, manufacturing, and retail and consumer, which ranged from $100M to $1B+ in revenues. He brings in credible skill in

Christina Lockhart

Christina focuses on management for rare disease and novel therapy studies. She has developed study management tools, processes and procedures that facilitate operations from study conception to study close-out. Prior to joining Aceragen, she spearheaded a COVID-19 treatment trial with the focus on rapid study take-off. With over 18 years’ working in pharma, biotech, CROs

Travis Autrey

Travis is the Senior Director of Finance at Aceragen, one of our team’s money management leaders. Prior to Aceragen, he worked for Ology Bioservices, Inc. as they built their contract development and manufacturing organization operations. There, he managed more than $1 billion dollars’ worth of government and commercial CDMO contracts, assisted in raising over $100

Bryan Hoang

Bryan serves as our Senior Manager of Project Management, a leader in therapy development processes. He has numerous patents and publications on targeted therapeutics, radioimmunotherapy, small molecule compounds and sustained drug delivery systems. Bryan has more than 10 years of experience in developing transformative medicines for the treatment of chronic indications including oncology, CNS diseases

Carl Kraus

Carl guides Aceragen researchers and doctors in their work to deliver safe, effective treatments. He is an Infectious Disease physician with more than 20 years’ experience in drug development, ranging from discovery and first-in-man studies through late-phase/risk-management program implementation. Carl has been the Principal Investigator for multiple NIAID, NCI and DoD-funded research programs and an